Antifungal Resistance: Current Trends and Future Strategies

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Fungal Pathogens".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 2370

Special Issue Editors


E-Mail Website
Guest Editor
1. Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy
2. Hospital Pharmacy, Azienda Ospedaliero Universitaria di Sassari, 07100 Sassari, Italy
Interests: antimicrobial resistance in nosocomial clinical microorganisms; infection; antimicrobial activity; essential oils; biofilm; biomaterials; ocular infections; orthopeadics infections
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Co-Guest Editor
Department of Biochemistry and Microbiology, Faculty of Pharmacy, Syrian Private University (SPU), Daraa International Highway, Daraa, Syria
Interests: clinical microbiology; antimicrobial resistance; sexually transmitted infections; pathogenic; virulence; bacteriology; mycology

Special Issue Information

Dear Colleagues,

For decades, fungal infections have been a difficult health condition to treat. This can be attributed to the narrow spectrum and high toxicity of clinically used antifungals, the long duration of treatment, and the high emergence of resistance towards available agents. The severity of fungal infections was brought to light during the unfortunate COVID-19 pandemic, in the form of life-threatening secondary infections in intensive care units. Candida, Cryptococcus, and Aspergillus are the most common causative organisms of life-threatening human fungal infections. Candida auris is a multidrug resistant fungus. Lomentospora prolificans has intrinsic resistance to all clinically used antifungals. Aspergillus fumigatus is becoming more resistant to treatment, making it more difficult to treat aspergillosis, with the mortality rate reaching 100% in some cases. Early diagnosis and treatment of fungal meningitis and chronic pulmonary aspergillosis can save millions of lives worldwide. Fungal infections have become a silent crisis, and immediate efforts are needed before it is too late. In this Special Issue, we will highlight current cutting-edge developments in the antifungal pipeline.

For this Special Issue, we invite you to submit original or review articles on new antifungal molecules, formulations, resistances, or studies.

Dr. Matthew Donadu
Dr. Basem Battah
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antifungal
  • resistance
  • anti-biofilm
  • new molecules
  • molecular resistance

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

17 pages, 1632 KiB  
Review
Nanotechnology-Based Strategies to Combat Multidrug-Resistant Candida auris Infections
by Helal F. Hetta, Yasmin N. Ramadan, Israa M. S. Al-Kadmy, Noura H. Abd Ellah, Lama Shbibe and Basem Battah
Pathogens 2023, 12(8), 1033; https://doi.org/10.3390/pathogens12081033 - 13 Aug 2023
Cited by 2 | Viewed by 2067
Abstract
An emerging multidrug-resistant pathogenic yeast called Candida auris has a high potential to spread quickly among hospitalized patients and immunodeficient patients causing nosocomial outbreaks. It has the potential to cause pandemic outbreaks in about 45 nations with high mortality rates. Additionally, the fungus [...] Read more.
An emerging multidrug-resistant pathogenic yeast called Candida auris has a high potential to spread quickly among hospitalized patients and immunodeficient patients causing nosocomial outbreaks. It has the potential to cause pandemic outbreaks in about 45 nations with high mortality rates. Additionally, the fungus has become resistant to decontamination techniques and can survive for weeks in a hospital environment. Nanoparticles might be a good substitute to treat illnesses brought on by this newly discovered pathogen. Nanoparticles have become a trend and hot topic in recent years to combat this fatal fungus. This review gives a general insight into the epidemiology of C. auris and infection. It discusses the current conventional therapy and mechanism of resistance development. Furthermore, it focuses on nanoparticles, their different types, and up-to-date trials to evaluate the promising efficacy of nanoparticles with respect to C. auris. Full article
(This article belongs to the Special Issue Antifungal Resistance: Current Trends and Future Strategies)
Show Figures

Graphical abstract

Back to TopTop